Fundraising Fox
Hongbo Lu
InvestorManaging Partner at Lilly Asia Ventures
Palo Alto, California
Writes $10M – $50M checks · typically $25M
Find your path to Hongbo
505 people in our graph can introduce you to Hongbo.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Evan Fu to introduce you to Hongbo
You →Evan · together at Lilly Asia Ventures (2020) →Hongbo
Ask Jamie Chen to introduce you to Hongbo
You →Jamie · 6 people · together at Lilly Asia Ventures →Hongbo
Ask Sam Okafor to introduce you to Hongbo
You →Sam · 5 people · together at Vivo Capital →Hongbo
Sign up to find every way you can get introduced to Hongbo
- Your email: the people you already email who know Hongbo
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Hongbo
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Experience
- NEXTBio CapitalManaging Membercurrent2024 — presentMenlo Park, California, United States
- Vivo CapitalManaging Partner2020 — 2024
- Lilly Asia VenturesManaging Partner2017 — 2020San Francisco Bay Area
- OrbiMed AdvisorsManaging Director2011 — 2016
- Piper JaffraySenior Equity Analyst, Principal,2005 — 2011san francisco, california
- Zyomyx, Inc.Technology Planning and Strategies Manager2000 — 2004Hayward, California
Deals · 79
BlossomHill TherapeuticsBoard seat
via Lilly Asia Ventures · filed Jan 2024 · $100M raise
Rgenta TherapeuticsBoard seat
via Lilly Asia Ventures · filed Mar 2021 · $38M raise
Perfuse TherapeuticsBoard seat
via Lilly Asia Ventures · filed Jul 2020 · $39M raise
AvedroBoard seat
via Lilly Asia Ventures · filed May 2018 · $25M raise
ArriventSolo GP
via Lilly Asia Ventures · filed Dec 2022
Singleron BiotechnologiesSolo GP
via Lilly Asia Ventures · filed Nov 2021
AlebundSolo GP
via Lilly Asia Ventures · filed Sep 2021
Sonoma BiotherapeuticsSolo GP
via Lilly Asia Ventures · filed Jul 2021
NiKang TherapeuticsSolo GP
via Lilly Asia Ventures · filed May 2021
RegorSolo GP
via Lilly Asia Ventures · filed Feb 2021
Terns PharmaceuticalsSolo GP
via Lilly Asia Ventures · filed Dec 2020
Insilico MedicineSolo GP
via Lilly Asia Ventures · filed Sep 2019
KSQ TherapeuticsSolo GP
via Lilly Asia Ventures · filed Sep 2018
MetacrineSolo GP
via Lilly Asia Ventures · filed Jun 2018
SingleraSolo GP
via Lilly Asia Ventures · filed Mar 2018
Tmunity TherapeuticsSolo GP
via Lilly Asia Ventures · filed Jan 2018
Gritstone OncologySolo GP
via Lilly Asia Ventures · filed Sep 2017
NuVera MedicalSolo GP
via Lilly Asia Ventures · filed Jun 2017
AllistSolo GP
Ansun BiopharmaSolo GP
Connect BiopharmaSolo GP
CorrectsequenceSolo GP
Crown BioScienceSolo GP
Cullinan OncologySolo GP
EdiGeneSolo GP
GeneceptionSolo GP
GeneseeqSolo GP
GracellbioSolo GP
HuamaitaikeSolo GP
InhibrxSolo GP
InventisbioSolo GP
IonovabioSolo GP
JacobiopharmaSolo GP
Legend BiotechSolo GP
Lupeng PharmaceuticalSolo GP
LYNK PharmaceuticalsSolo GP
MicrotechmdSolo GP
MilliinSolo GP
NextCureSolo GP
Profound BioSolo GP
ReadCoorSolo GP
RonatherapeuticsSolo GP
Tempest TherapeuticsSolo GP
迪哲医药 (Dizal Pharma)Solo GP
3SbioSolo GP
AbbiskoSolo GP
AceabioSolo GP
AirdocSolo GP
ARMO BioSciencesSolo GP
AusunpharmSolo GP
BettapharmaSolo GP
BrbiotechSolo GP
CansinotechSolo GP
CarsgenSolo GP
ChinesepeptideSolo GP
ChipscreenSolo GP
ElpiscienceSolo GP
Fountain MedSolo GP
HD BiosciencesSolo GP
IMPACT TherapeuticsSolo GP
Innovent BiologicsSolo GP
JustbiochinaSolo GP
MabspacebioSolo GP
MediTrust HealthSolo GP
NewhorizonbioSolo GP
NovastSolo GP
PinsmedicalSolo GP
RemegenSolo GP
SinqiSolo GP
SperogenixSolo GP
SzyhloSolo GP
TargetingoneSolo GP
Turning Point TherapeuticsSolo GP
VirtuedxSolo GP
XihuasciSolo GP
凯因科技Solo GP
博瑞医药Solo GP
圣湘生物Solo GP
Attribution from SEC filings, press coverage, and firm rosters. Some rows are inferred. Not right? Tell us.
Other disclosed investments
Board seats
Per SEC Form D filings.
Colleagues at Lilly Asia Ventures
Frequently asked questions
- Who is Hongbo Lu?
- Managing Partner at Lilly Asia Ventures
- Where does Hongbo Lu work?
- Hongbo Lu is Managing Partner at Lilly Asia Ventures.
- What check size does Hongbo Lu write?
- Hongbo Lu typically writes checks of $10M – $50M.
- What boards does Hongbo Lu sit on?
- Hongbo Lu holds tracked board seats at ADARx Pharmaceuticals, Avedro, BlossomHill Therapeutics, Perfuse Therapeutics, Rgenta Therapeutics.
- Where did Hongbo Lu go to school?
- Hongbo Lu studied at University of California, Berkeley, Haas School of Business (MBA, Finance); University of Washington (PhD, Bioengineering); Tsinghua University (BS).
Same school
Also attended University of California, Berkeley, Haas School of Business971
+ 965 more
Also attended University of Washington623
+ 617 more
Also attended Tsinghua University307
+ 301 more
Shared employers
Also worked at Vivo Capital23
+ 17 more
Also worked at Lilly Asia Ventures7
+ 1 more
Also worked at OrbiMed Advisors70
+ 64 more
Also worked at Piper Jaffray102
+ 96 more